TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
NCT00260403 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2006-02-03
Summary
The purpose of the study is to compare photodynamic therapy to transpupillary thermotherapy as a treatment method for choroidal neovascularization in age-related macular degeneration ( AMD). AMD is a disease affecting the macula, the central area of the retina.There are two main types of AMD. Geographic atrophy ( dry) AMD and neovascular ( wet) AMD. In neovascular AMD, sub-retinal neovascular membranes ( new blood vessels) develop beneath the retina. The new vessels can leak causing haemorrhage that leads to significant visual loss. Photodynamic therapy ( PDT) is a method for treating neovascular membranes without affecting the retina. Photoactive chemicals are injected into the patient and irradiated with light as the pass through the neovascular membranes. This light is strong enough to activate the chemicals, that destroy the blood vessels, but not strong enough to cause damage to the overlying retina. The duration of the treatment is 83s. PDT treatment is effective in predominantly classic subfoveal choroidal neovascularization ( CNV), but was observed to yield no visual benefit in minimally classic CNV during a 2-year follow-up and as to occult CNV the effect was scarce. PDT does have its drawbacks, one of which is the cost. Another is that the patient become highly sensitive to strong light. Transpupillary thermotherapy ( TTT) is a thermic treatment of choroidal neovascularization in AMD. Using a thermal diode laser ( emission 810 nm), transpupillary irradiation of the fundus through a conventinal contact lens is performed. The temperature is elevated \< 10 degrees C during a 60s exposure to continuous radiation. The laser power is adjusted to the diameter of the laser beam. In a pilot study, Reichel et al. ( 1999) demonstrated that subfoveal occult CNV could be occluded and visual acuity stabilized in a majority of patients treated with TTT. These results has been confirmed in small series of cases with occult CNV and with minimally ( \<50%) classic CNV. This prospective, randomized controlled study aim to compare TTT and PDT as a treatment for occult and minimally classic CNV. A total of 140 patients will be included in the study. Follow up is 2 years. The patients included will be followed as to visual acutiy ( ETDRS), new vessel growth ( fluorescien angiography and ICG), OCT and with a quality of life questionnarie.
Conditions
- Choroidal Neovascularization
Interventions
- PROCEDURE
-
Photodynamic therapy versus Transpupillary thermotherapy
Sponsors & Collaborators
-
St. Erik Eye Hospital
lead OTHER
Principal Investigators
-
Anne C Odergren, MD · St Eriks Eye Hospital
-
Stefan Seregard, Professor · St Eriks Eye Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-06-30
- Completion
- 2008-01-31
Countries
- Sweden
Study Locations
More Related Trials
-
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
NCT00696592 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
NCT03680326 ·Status: COMPLETED
-
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
NCT00347399 ·Status: TERMINATED ·Phase: PHASE2
-
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
NCT00684853 ·Status: UNKNOWN ·Phase: PHASE2
-
The Avastin vs Visudyne for Neovascular AMD Study
NCT00390026 ·Status: WITHDRAWN ·Phase: PHASE3
-
Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone
NCT00685100 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
NCT00729846 ·Status: COMPLETED ·Phase: PHASE2
-
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
NCT02367365 ·Status: COMPLETED
-
Initial Versus Delayed PDT Combination With Conbercept in PCV
NCT02821520 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
NCT00426998 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
NCT00359164 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
NCT04800679 ·Status: UNKNOWN ·Phase: PHASE2
-
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
NCT00403442 ·Status: TERMINATED ·Phase: PHASE1
-
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00727753 ·Status: COMPLETED
-
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT01256580 ·Status: WITHDRAWN ·Phase: NA
-
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
NCT00709657 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia
NCT00967850 ·Status: COMPLETED ·Phase: PHASE3
-
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806 ·Status: COMPLETED
-
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
NCT01350323 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Bevacizumab for Diabetic Retinopathy
NCT00600262 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
NCT00370370 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF
NCT02876198 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Age-Related Macular Degeneration
NCT00347165 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Therapy for Neovascular Age Related Macular Degeneration
NCT00447031 ·Status: WITHDRAWN ·Phase: NA